Abstract 214P
Background
Urothelial carcinoma (UC), including upper tract UC (UTUC) and UC of the bladder (UCB), is one of the most common malignancies worldwide. The current standard methods for diagnosis and monitoring of UC are often invasive and/or lack sensitivity and specificity. Emerging evidence has shown that urinary RNAs could potentially serve as promising biomarkers for UC diagnosis. In this study, we intended to develop and validate an accurate and noninvasive urine RNA test for UC diagnosis and monitoring.
Methods
Gene expression profiling of our previously reported 32 RNA targets were analyzed TaqMan qPCR arrays. We pooled all samples analyzed before to obtain a larger training set and develop a diagnostic gene panel. The identified gene panel was then validated in a large-scale independent cohort of 752 patients. Voided urine specimens were prospectively collected at 3 hospitals from subjects scheduled for tumor surgery or endoscopy for the urinary tract due to suspicious symptoms. The sensitivity and specificity of the gene panel were evaluated using endoscopy and/or histologic diagnosis as a reference.
Results
An eight-gene panel (CA9, CCL18, ERBB2, IGF2, MMP12, PPP1R14D, SGK2 and SWINGN) was developed. In the prospective cohort, the gene panel achieved 93.4%overall accuracy (702/752), 92.3% sensitivity (275/298) and 94.1% specificity (427/454). High sensitivity was maintained in low grade (89.9%, 62/69), early stage (88.5%, 115/130) and residual tumors (89.5%, 34/38). Notably, the gene panel accurately detected UTUCs with 97.3% (36/37) sensitivity, indicating that urinary RNA targets selected here were relevant markers for both UTUC and UCB. Besides, the specificity among other malignancies like prostate cancer, renal cancer, etc. reached 94.5% (173/183). With respect to surveillance, the gene panel showed 88.6% sensitivity and 98.2% specificity for detecting recurrences in 136 patients.
Conclusions
In summary, the eight-gene urine test showed superior sensitivity and specificity for diagnosis of UCs across all tumor stages, grades and sites, hence might represent a promising tool for noninvasive UC detection and surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Canhelp Genomics.
Disclosure
Y. Wo, Z. Luo, J. Chen, Q. Xu: Financial Interests, Personal, Full or part-time Employment: Canhelp Genomics. All other authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract